Aligos Therapeutics, Inc. (ALGS) Q1 2024 Earnings
ALGS·Reported May 7, 2024·After market close
Aligos Therapeutics, Inc. reported Q1 2024 revenue of $986.0K. Diluted EPS came in at $-5.50, missed the $-4.75 consensus by $0.75.
Revenue
$986.0K
Diluted EPS
$-5.50missed by $0.75
Consensus: $-4.75
Financial Snapshot
Trailing eight quarters through Q1 2024
Q1 2024 Earnings FAQ
Common questions about Aligos Therapeutics, Inc.'s Q1 2024 earnings report.
Aligos Therapeutics, Inc. (ALGS) reported Q1 2024 earnings on May 7, 2024 after market close.
Aligos Therapeutics, Inc. reported revenue of $986.0K and diluted EPS of $-5.50 for Q1 2024.
EPS missed the consensus estimate of $-4.75 by $0.75.
You can read the 10-Q periodic report (0000950170-24-054497) directly on SEC EDGAR. The filing index links above go to sec.gov.